Skip to main content
. 2017 Apr 27;8(24):38099–38112. doi: 10.18632/oncotarget.17485

Figure 1. Chloroquine treatment upregulates mevalonate pathway genes in TSC2-deficient cells.

Figure 1

A. Transcriptional profiling (978 genes) of human kidney angiomyolipoma-derived cells (621-101) treated with CQ (5uM) for 24 hours (six biological replicates) using L-1000 platform. Supervised clustering of the top 20 up and downregulated genes compared to untreated 621-101 cells. B. Validation of upregulated mevalonate pathway genes by qRT-PCR after 24 hours CQ treatment of 621-101 cells. C. Expression levels of mevalonate pathway genes in Tsc2+/+ and Tsc2−/− mouse embryonic fibroblasts (MEFs). Bar graph represents means ±SD of values relative to their vehicle control (H20). One sample t-test was used to compare mRNA expression levels between treated and untreated conditions; *p < 0.05, **p < 0.01. See also Supplementary Table 1. D. Concise schematic of the mevalonate pathway with key genes highlighted in red.